Merck has disclosed initial first-in-human clinical data for MK-2010, a bispecific antibody designed to simultaneously block the PD-1 and VEGF pathways, in a presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. The readout marks a critical early step in Merck’s effort to develop next-generation immuno-oncology backbones as its pembrolizumab (Keytruda) franchise faces mounting competitive pressure.
Mechanistic Rationale: Combining Immune Checkpoint Blockade and Anti-Angiogenesis
The dual targeting of PD-1 and VEGF reflects a well-supported biological rationale. VEGF-driven angiogenesis promotes an immunosuppressive tumor microenvironment, and its inhibition has been shown to enhance T-cell infiltration and potentiate responses to checkpoint blockade. By co-targeting both axes within a single bispecific molecule, MK-2010 is designed to achieve improved spatial co-engagement and pharmacodynamic coordination compared with the combination of two separate antibodies.
First-in-Human Clinical Profile
The early clinical data presented at AACR 2026 represent the first reported human evidence for MK-2010’s safety and biological activity. While Phase 1 readouts are inherently preliminary, the data position MK-2010 as a viable candidate for broader clinical development and potential advancement into registrational studies across multiple tumor types.
Specific efficacy parameters and patient-level outcomes from the Phase 1 cohort were presented at the meeting, with the company monitoring the signal carefully as it determines indication prioritization.
The Competitive Backdrop: Ivonescimab and the Race Beyond Pembrolizumab
The MK-2010 disclosure carries added strategic weight given the competitive dynamics reshaping the IO landscape. Ivonescimab, a PD-1/VEGF bispecific developed by Akeso and being commercialized in certain markets by Summit Therapeutics, has generated significant attention following reported superiority data over pembrolizumab in non-small cell lung cancer in a China-based trial. Those results have raised questions about whether PD-1/VEGF bispecifics may outperform monotherapy checkpoint inhibitors as IO treatment backbones, a question Merck is now directly addressing with MK-2010.
Strategic Significance for Merck
Pembrolizumab faces biosimilar competition beginning in the latter part of this decade. The advancement of MK-2010 signals Merck’s recognition that its next-generation IO strategy must extend beyond PD-1 monotherapy and capitalize on validated combination targets that can sustain its oncology leadership position. A successful MK-2010 development program would represent one of the most significant pipeline inflections in the company’s recent history.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada